Abraxane monotherapy is indicated for the treatment of metastatic breast cancer The recommended dose of Abraxane in combination with gemcitabine is Attachment 1: Product information for AusPAR Abraxane paclitaxel (nab) Abraxis PM Date of Finalisation 17 June This Product. Learn more about ABRAXANE®, including dosing, efficacy, and safety information. This site is intended for US healthcare professionals only.

Author: Kesida Kektilar
Country: Saudi Arabia
Language: English (Spanish)
Genre: Life
Published (Last): 28 June 2012
Pages: 63
PDF File Size: 14.60 Mb
ePub File Size: 11.82 Mb
ISBN: 375-5-58762-223-9
Downloads: 73114
Price: Free* [*Free Regsitration Required]
Uploader: Nehn

ABRAXANE | Full Prescribing Information

The data collected included age, date of diagnosis, surgery, estrogen and progesterone receptor status, human epidermal growth factor receptor 2 status, sites of metastasis, initial tumour stage and lymph node status, histologic diagnosis, endocrine therapy, prior chemotherapy regimens, nab-paclitaxel administration duration of therapy, dosing schedule, reasons for nab-paclitaxel usetoxicities, dose reductions, clinical benefit, and date of death.

The dose-dependent antitumour response from paclitaxel can be decreased as a result Most patients also had several sites of metastases Dose reductions, mainly because of toxicity, were more common with q3w administration J Natl Cancer Inst. Patients alive or lost to follow up as of December 31,were censored. Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel [abstract ] J Clin Oncol.


Peripheral sensory neuropathy was the most commonly reported toxicity, being reported in approximately More than twice as many dose reductions occurred in the nab-paclitaxel q3w group In addition, it has been suggested that the Cremophor solvent used in the preparation of paclitaxel may have a direct negative effect on the antitumour properties of that drug Of 43 women mean age: Find articles by G.

Steroid premedication was not oi before administration of therapy.

Paclitaxel is entrapped by the formation of plasma Cremophor EL micelles, which can cause reduced drug clearance, nonlinear pharmacokinetics, and free drug fraction Nab-paclitaxel was administered weekly qw: Journal List Curr Oncol v.

Between June and December43 patients with mbc received treatment with single-agent nab-paclitaxel at the Ottawa Hospital Cancer Centre, and 42 patients were evaluable for clinical response. Nab-paclitaxel is a colloidal suspension of paclitaxel and human serum albumin that can be administered without premedication Abraxane PI, Abraxane PM: Nab-paclitaxel, taxane, mbcAbraxane.

ABRAXANE – Prescribing Information

National Center for Biotechnology InformationU. Retrospective data obtained included demographics, disease characteristics, prior chemotherapy, nab-paclitaxel treatment, toxicity, and survival. Patients who had received taxane docetaxel or paclitaxel chemotherapy adjuvant or metastatic setting before receiving nab-paclitaxel pj also included.

Abaxane odds ratio for achieving clinical benefit with the qw schedule was 2. The optimal dose and schedule of nab-paclitaxel has yet to be clearly defined. Women receiving nab-paclitaxel had a median overall survival of Find articles by J. It is this drug entrapment phenomenon that partly explains why giving higher doses of solvent-based paclitaxel does not result in improved clinical efficacy Open in a separate window.


Clinical benefit was based on clinical and radiologic assessments for example, computed tomography imaging of patients, which were requested by the treating physicians at variable points in time.

Copyright Multimed Inc. Nab-paclitaxel is a solvent-free, taxane-based chemotherapy approved for the treatment of metastatic breast cancer mbc.

Failure of higher-dose paclitaxel to xbraxane outcome in patients with metastatic breast cancer: Nab-paclitaxel treatment was given to 20 patients In our small single-institution retrospective study, most women with mbc who received nab-paclitaxel experienced some degree of clinical benefit qw The results of abraxanne randomized phase ii study in women with mbc suggest that weekly dosing of nab-paclitaxel qw: Find articles by M. Cremophor EL—mediated alteration of paclitaxel distribution in human blood: